Universal Time: 20:49  |  Local Time: 20:49 (3h GMT)
Select your timezone:

Abstract Session
Transplant immunosuppression 2

Tuesday September 24, 2024 | 08:00 to 09:15
Room: TBD
Track: N/A

Presentations

Prof. Esra Baskin, Turkey Invited Speaker
Immunosuppression in kidney Tx for children

Dr. Ebru Sevinc Ok, Turkey
Results of MMF+EVO combination in drug switching after kidney transplantation.

Andrew Santeusanio, United States
Comparison of actual versus ideal body weight based dosing of anti-thymocyte globulin in kidney transplant recipients

Dr. Bradley J Gardiner, Australia
Quantiferon®-monitor as a biomarker of immunosuppression and predictor of infection: A scoping review

Dr. Amit S Pasari, India
CYP3A5 Polymorphism in Kidney Transplantation: Individualizing Tacrolimus Dosing

Dr. HINAL RAMUBHAI RATHOD Dr., India
Observational study of factors affecting Tacrolimus trough level in renal transplant patients

Dr. Huseyin Akilli, Turkey
Atypical cervical cytology in solid organ transplantation patients: 20 years of experience in a single center

Alain Assounga, South Africa
High intra patient variability (IPV) of serum tacrolimus is associated with a worsening serum creatinine in tkidney transplant patients attening Inkosi Albert Luthuli Central Hospital, Durban, South Africa.

Dr. Sergio DJ. Salcedo Herrera Sr., Colombia
Correlating Tacrolimus Levels with Dose Formulation: Implications for Toxicity and Renal Graft Rejection in a cohort of kidney Transplant Recipients with Steroid-free maintenance immunosuppression.

Mrs. Ariunaa Ari Altangerel, Mongolia
Identification of cytokine profiles in blood samples from kidney transplant recipients

Social Media Promotion Image

right-click to download

© 2024 TTS 2024